RecruitingPhase 2NCT06680739

Single cEll pRofiling PErsistaNce To ImmuNothErapy

Single Cell Characterization of Persistent Cells Upon Treatment With Durvalumab (MEDI4736) With or Without Tremelimumab in MSS and MSI Colorectal and Endometrial Tumors: the SERPENTINE Clinical Trial

Sponsor

Vall d'Hebron Institute of Oncology

Enrollment

60 participants

Start Date

Mar 1, 2022

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer Endometrial Cancer

Summary

The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer. The trial targets patients with microsatellite instability-high (MSI-H) tumors and those with microsatellite stable (MSS) tumors. Colorectal and endometrial cancers present significant challenges due to their heterogeneity and variable responses to treatment. Immunotherapy, particularly checkpoint inhibitors like durvalumab and tremelimumab, has shown promise in some patients, but predicting response remains elusive. The SERPENTINE trial aims to address this gap by investigating the effectiveness of these immunotherapies in a carefully selected patient population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects detailed biological samples from cancer patients receiving immunotherapy to understand why some patients' cancers keep responding to treatment while others stop responding. The findings aim to improve future cancer immunotherapy strategies. **You may be eligible if...** - You are 18 or older - You are in generally good physical condition (ECOG 0 or 1) - You have colorectal cancer (CRC) or endometrial cancer (uterine cancer), regardless of prior treatment, OR you have non-small cell lung cancer (NSCLC), bladder cancer, or head and neck cancer and are about to start your first immunotherapy treatment **You may NOT be eligible if...** - You are in poor physical health (ECOG 2 or higher) - You are not willing to provide blood and tissue samples as required by the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.